GLPwatch

GLP‑1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy.

Sci Rep · 2023

Last updated 2026-05-28

In lab tests on rat muscle cells, the GLP-1 drug liraglutide (doses from 10 to 1000 nM) reversed insulin resistance caused by palmitate (0.6 mM). The drug worked by boosting a protein called Sestrin2, which in turn increased autophagy, a cellular cleanup process.

AI summary of the abstract below.

JournalSci Rep, 2023
Citations23
Relative citation ratio2.98
NIH percentile84
Molecules
Conditions studied Type 2 Diabetes

Abstract

In this study, we aimed to determine whether liraglutide could effectively reduce insulin resistance (IR) by regulating Sestrin2 (SESN2) expression in L6 rat skeletal muscle cells by examining its interactions with SESN2, autophagy, and IR. L6 cells were incubated with liraglutide (10-1000 nM) in the presence of palmitate (PA; 0.6 mM), and cell viability was detected using the cell counting kit-8 (CCK-8) assay. IR-related and autophagy-related proteins were detected using western blotting, and IR and autophagy-related genes were analyzed using quantitative real-time polymerase chain reaction. Silencing SESN2 was used to inhibit the activities of SESN2. A reduction in insulin-stimulated glucose uptake was observed in PA-treated L6 cells, confirming IR. Meanwhile, PA decreased the levels of GLUT4 and phosphorylation of Akt and affected SESN2 expression. Further investigation revealed that autophagic activity decreased following PA treatment, but that liraglutide reversed this PA-induced reduction in autophagic activity. Additionally, silencing SESN2 inhibited the ability of liraglutide to up-regulate the expression of IR-related proteins and activate autophagy signals. In summary, the data showed that liraglutide improved PA-induced IR in L6 myotubes by increasing autophagy mediated by SESN2.

Verbatim abstract via PubMed 37296162 ↗